deltatrials
Completed OBSERVATIONAL NCT01601119

Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients

The Impact of Disease Modifying Therapies (DMTs) and Associated Support Services on Patient Reported Experience Measures (PREMs) and Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients

Sponsor: Merck KGaA, Darmstadt, Germany

Conditions Relapsing Multiple Sclerosis
Interventions Other: Disease modifying therapies (DMT) Rebif
Updated 8 times since 2017 Last updated: May 28, 2015 Started: Jan 31, 2012 Primary completion: Jul 31, 2014 Completion: Jul 31, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Relapsing Multiple Sclerosis, this trial is completed. The trial is conducted by Merck KGaA, Darmstadt, Germany and has accumulated 8 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Apr 2018 · 15 months · monthly snapshotCompleted~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2019 · 7 months · monthly snapshotCompleted~Jan 2019 – ~Jan 2021 · 24 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 9 months · monthly snapshotCompleted

Change History

8 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed

  2. Sep 2024 — Sep 2025 [monthly]

    Completed

  3. Jul 2024 — Sep 2024 [monthly]

    Completed

  4. Jan 2021 — Jul 2024 [monthly]

    Completed

  5. Jan 2019 — Jan 2021 [monthly]

    Completed

▶ Show 3 earlier versions

  1. Jun 2018 — Jan 2019 [monthly]

    Completed

  2. Apr 2018 — Jun 2018 [monthly]

    Completed

    Phase: NA → None

  3. Jan 2017 — Apr 2018 [monthly]

    Completed NA

    First recorded

Jan 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck KGaA, Darmstadt, Germany
  • Merck Serono Limited, UK
Data source: Merck KGaA, Darmstadt, Germany

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations